Torbay Pharma on-boards Strong Leaders to boost its North American growth strategy

Torbay Pharma, a global leader in manufacturing and supplying terminally sterilised injectables for the secondary care market, has on-boarded strong influencing professionals in the industry to strengthen its senior leadership team and to support its North American growth strategy, as reported.

NorthEdge, a private equity firm, recently invested in Torbay Pharma, a contract manufacturer and license holder company. The industry leaders with extensive experience in executive roles, Mohammed Nazir (Naz) and Tara Slivey are the newly appointed COO and CPO, respectively.  

Naz has developed his operational expertise in Pantheon and Pfizer and will support the company in crafting manufacturing growth plans. Tara has substantial experience working with people from diverse backgrounds and pharmaceutical manufacturing businesses owned by private equity. 

Torbay Pharma's CEO, Emma Rooth, says, “As we expand in North America, we focus on innovation, efficiency, and, most importantly, patient wellbeing. In addition to bolstering our leadership team to supercharge our growth, we’re currently working with the FDA to support our bid to gain approval.

“The expansion couldn’t come at a more crucial time as the healthcare sector in the US grapples with supply chain challenges and increasing demand for essential medicines. Many of the products we manufacture are already at the top of the US shortage list, highlighting the indispensable role Torbay Pharma can play.”

Torbay Pharma is known for its specialist expertise in filling generic injectables into plastic and glass containers. The company has witnessed a rise in demand for plastic parenteral nutrition (PN) products across the North American region within the last two years.

 Facebook